COX-2/sEH-IN-1

MedChemExpress

®

Cat. No.:	HY-146704	
CAS No.:	2474977-38-1	NH ₂
Molecular Formula:	C ₂₃ H ₁₈ F ₃ N ₅ O ₃ S	0 S≈O
Molecular Weight:	501.48	_ F
Target:	Epoxide Hydrolase; COX	
Pathway:	Metabolic Enzyme/Protease; Immunology/Inflammation	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

Product Data Sheet

Discourse vertret Description COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC ₅₀ values of 1.24 µM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks ^[1] . Ic ₅₀ & Target SEH COX-2 COX-1 0.40 nM (IC ₅₀) 1.24 µM (IC ₅₀) 8.72 µM (IC ₅₀) In Vivo COX-2/sEH-IN-1 (Compound 9c) (10 mg/kg; p.o.; onc) exhibits analgesic activity ^[1] . COX-2/sEH-IN-1 (COMP/kg, p.o.; onc) shows high anti-inflammatory activity ^[1] . COX-2/sEH-IN-1 (100 mg/kg; p.o.; onc) exhibits analgesic activity ^[1] . COX-2/sEH-IN-1 (100 mg/kg; p.o.; onc) shows high anti-inflammatory activity ^[1] . COX-2/sEH-IN-1 (100 mg/kg; p.o.; onc) shows high anti-inflammatory activity ^[1] . COX-2/sEH-IN-1 (100 mg/kg; p.o.; onc) shows high anti-inflammatory activity ^[1] . COX-2/sEH-IN-1 (100 mg/kg; p.o.; onc) shows high anti-inflammatory activity ^[1] . COX-2/sEH-IN-1 (100 mg/kg; p.o.; once) shows high anti-inflammatory activity ^[1] . COX-2/sEH-IN-1 (100 mg/kg Dosage: 10 mg/kg Albino mice (20-30 g) ^[1] Dosage: 10 mg/kg Administration, once Result: Exhibited analgesic activity with 65.67% inhibition in the number of writhing. Administration: Oral administration, once Result:					
Description COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC ₅₀ values of 1.24 µM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular-isks ¹¹ . IC ₅₀ & Target SEH 0.40 nM (IC ₅₀) COX-2 1.24 µM (IC ₅₀) COX-1 8.72 µM (IC ₅₀) In Vivo COX-2/sEH-IN-1 (Compound 9c) (10 mg/kg; p.o.; once) shows high anti-inflammatory activity ¹¹ . COX-2/sEH-IN-1 (50 mg/kg; p.o.; once) shows high anti-inflammatory activity ¹¹ . COX-2/sEH-IN-1 (50 mg/kg; p.o.; once) shows high anti-inflammatory activity ¹¹ . COX-2/sEH-IN-1 (100 mg/kg; p.o.; aveeks) affords a perfect cardio-protection and less cardiovascular liabilities ¹¹ . Minal Model: Albino mice (20-30 g) ¹¹ Dosage: 10 mg/kg Ing/kg Animal Model: Albino mice (20-30 g) ¹¹ Dosage: 50 mg/kg Animal Model: Albino rats (120-150 g), carrage=nan-induced paw edema model ^{[11}] Dosage: 50 mg/kg Administration: Oral administration, once Result: Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 98.15% at 1, 3, 5 h, respectively. Animal Model: Adult male albino Wister rats (IT-200 g) ^{[11} Dosage: 100 mg/kg	BIOLOGICAL ACTIV				
IS so & Target SEH 0.40 m (IC S0) COX-2 1.24 µ (IC (S0) COX-1 8.72 µ (IC (S0) In Vivo COX-2/SEH-IN-1 (Compound-SC) on cole exhibits and series activity ^[1] . COX-2/SEH-IN-1 (100 mg/kg; p.o.; once) shows high anti-inflammatory activity ^[1] . COX-2/SEH-IN-1 (100 mg/kg; p.o.; once) shows high anti-inflammatory activity ^[1] . COX-2/SEH-IN-1 (100 mg/kg; p.o.; once) shows high anti-inflammatory activity ^[1] . COX-2/SEH-IN-1 (100 mg/kg; p.o.; once) shows high anti-inflammatory activity ^[1] . COX-2/SEH-IN-1 (100 mg/kg; p.o.; once) shows high anti-inflammatory activity ^[1] . COX-2/SEH-IN-1 (100 mg/kg; p.o.; once) shows high anti-inflammatory activity ^[1] . COX-2/SEH-IN-1 (100 mg/kg; p.o.; once) shows high anti-inflammatory activity with 65.67% inhibition in the number of writhing. Animal Model: Albino rats (120-150 g), carrage-in-induced paw edema model ^[1] . Dosage: Animal Model: Oral administration, once Result: Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 91.55% at 1, 3, 5 h, respectively. Animal Model: Adult male albino Wister rats (170-200 g) ^[1] .	Description	COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC ₅₀ values of 1.24 μM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks ^[1] .			
In Vivo COX-2/SEH-IN-1 (Compound 9c) (10 mg/kg; p.o.; once) exhibits analgesic activity ^[11] . COX-2/SEH-IN-1 (50 mg/kg; p.o.; once) shows high anti-inflammatory activity ^[11] . COX-2/SEH-IN-1 (100 mg/kg; p.o.; 2 weeks) affords a perfect cardio-protection and less cardiovascular liabilities ^[11] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Albino mice (20-30 g) ^[11] Dosage: 10 mg/kg Administration: Oral administration, once Result: Showed high anti-inflammatory activity with 65.67% inhibition in the number of writhing. Administration: Oral administration, once Result: Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 98.15% at 1, 3, 5 h, respectively. Animal Model: Adult male albino Wister rats (170-200 g) ^[1] Dosage: 100 mg/kg	IC ₅₀ & Target	sEH 0.40 nM (IC ₅₀)	COX-2 1.24 μΜ (IC ₅₀)	COX-1 8.72 μM (IC ₅₀)	
Animal Model:Albino mice (20-30 g) ^[1] Dosage:10 mg/kgAdministration:Oral administration, onceResult:Exhibited analgesic activity with 65.67% inhibition in the number of writhing.Animal Model:Albino rats (120-150 g), carrageenan-induced paw edema model ^[1] Dosage:50 mg/kgAdministration:Oral administration, onceResult:Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 98.15% at 1, 3, 5 h, respectively.Animal Model:Adut male albino Wister rats (170-200 g) ^[1] Dosage:100 mg/kg	In Vivo	COX-2/sEH-IN-1 (Compound 9c) (10 mg/kg; p.o.; once) exhibits analgesic activity ^[1] . COX-2/sEH-IN-1 (50 mg/kg; p.o.; once) shows high anti-inflammatory activity ^[1] . COX-2/sEH-IN-1 (100 mg/kg; p.o.; 2 weeks) affords a perfect cardio-protection and less cardiovascular liabilities ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
Dosage:10 mg/kgAdministration:Oral administration, onceResult:Exhibited analgesic activity with 65.67% inhibition in the number of writhing.Animal Model:Albino rats (120-150 g), carrageenan-induced paw edema model ^[1] Dosage:50 mg/kgAdministration:Oral administration, onceResult:Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 98.15% at 1, 3, 5 h, respectively.Animal Model:Adult male albino Wister rats (170-200 g) ^[1] Dosage:100 mg/kg		Animal Model:	Albino mice (20-30 g) ^[1]		
Administration:Oral administration, onceResult:Exhibited analgesic activity with 65.67% inhibition in the number of writhing.Animal Model:Albino rats (120-150 g), carrageenan-induced paw edema model ^[1] Dosage:50 mg/kgAdministration:Oral administration, onceResult:Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 98.15% at 1, 3, 5 h, respectively.Animal Model:Adult male albino Wister rats (170-200 g) ^[1] Dosage:100 mg/kg		Dosage:	10 mg/kg		
Result:Exhibited analgesic activity with 65.67% inhibition in the number of writhing.Animal Model:Albino rats (120-150 g), carrageenan-induced paw edema model ^[1] Dosage:50 mg/kgAdministration:Oral administration, onceResult:Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 98.15% at 1, 3, 5 h, respectively.Animal Model:Adult male albino Wister rats (170-200 g) ^[1] Dosage:100 mg/kg		Administration:	Oral administration, once		
Animal Model:Albino rats (120-150 g), carrageenan-induced paw edema model ^[1] Dosage:50 mg/kgAdministration:Oral administration, onceResult:Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 98.15% at 1, 3, 5 h, respectively.Animal Model:Adult male albino Wister rats (170-200 g) ^[1] Dosage:100 mg/kg		Result:	Exhibited analgesic activity with 65.67% inhibition in the number of writhing.		
Dosage:50 mg/kgAdministration:Oral administration, onceResult:Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 98.15% at 1, 3, 5 h, respectively.Animal Model:Adult male albino Wister rats (170-200 g) ^[1] Dosage:100 mg/kg		Animal Model:	Albino rats (120-150 g), carrageenan-induced paw edema model $^{[1]}$		
Administration: Oral administration, once Result: Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 98.15% at 1, 3, 5 h, respectively. Animal Model: Adult male albino Wister rats (170-200 g) ^[1] Dosage: 100 mg/kg		Dosage:	50 mg/kg		
Result: Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 98.15% at 1, 3, 5 h, respectively. Animal Model: Adult male albino Wister rats (170-200 g) ^[1] Dosage: 100 mg/kg		Administration:	Oral administration, once		
Animal Model:Adult male albino Wister rats (170-200 g) ^[1] Dosage:100 mg/kg		Result:	Showed high anti-inflammatory activity with edema inhibition of 64.06%, 95.82%, and 98.15% at 1, 3, 5 h, respectively.		
Dosage: 100 mg/kg		Animal Model:	Adult male albino Wister rats (1	.70-200 g) ^[1]	
		Dosage:	100 mg/kg		

Administration:	Oral administration, 2 weeks
Result:	Exhibited a significant lowering in Troponine-I, LDH and CK-MB levels when compared to celecoxib treated group. Showed remarkably decrease in TNF-α concentration compare to the celecoxib induced cardio-toxicity group. Restored heart GSH level and significant
	increased PGI2 level compared to celecoxib group. Showed mild decongestant and mild edema on cardiac blood vessels and showed more or less normal muscle bundles.

REFERENCES

[1]. Ahmed H Abdelazeem, et al. Discovery of novel urea-diarylpyrazole hybrids as dual COX-2/sEH inhibitors with improved anti-inflammatory activity and highly reduced cardiovascular risks. Eur J Med Chem. 2020 Nov 1;205:112662.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA